ASOI – Position on Liraglutide 3.0mg via the HSE Medicines Management Programme
The Association for the Study of Obesity on the Island of Ireland and the Irish Coalition for People Living with Obesity welcome the HSE Medicines Management Programme approval for reimbursement for Liraglutide 3.0mg (Saxenda ®) for adults living with obesity and it’s cardiometabolic complications. It offers hope for the future for thousands of adults living … Read more